AET,Whistleblower files U.S. fraud suit against Cardinal HealthWhistleblower files U.S. fraud suit against Cardinal Health Healthcare services provider Cardinal Health Inc said its unit was accused of fraud and violating U.S. healthcare laws by a whistleblower under the False Claims Act.  Whistleblower files U.S. fraud suit against Cardinal Health Healthcare services provider Cardinal Health Inc said its unit was accused of fraud and violating U.S. healthcare laws by a whistleblower under the False Claims Act. Feb 3 Healthcare services provider Cardinal Health Inc said its unit was accused of fraud and violating U.S. healthcare laws by a whistleblower under the False Claims Act.Whistleblower files U.S. fraud suit against Cardinal Health Healthcare services provider Cardinal Health Inc said its unit was accused of fraud and violating U.S. healthcare laws by a whistleblower under the False Claims Act.  
ALL,Allstate profit falls 1.9 pct Feb 4 Allstate Corp, the largest publicly traded home and auto insurer in the United States, reported a 1.9 percent fall in quarterly profit as it paid out more in claims. 
ADP,US STOCKS-Futures dip after 2-day run; ADP data on tapU.S. private sector adds 213,000 workers in January: ADPTREASURIES-U.S. yields jump after ADP U.S. jobs dataUS STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)      US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     NEW YORK, Feb 4 U.S. Treasuries yields rose on Wednesday after the January reading on a gauge on U.S. private jobs creation supported the view of steady domestic employment growth and revived bets the Federal Reserve might raise interest rates in mid-2015.US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)       TREASURIES-U.S. yields jump after ADP U.S. jobs dataUS STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)      US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     NEW YORK, Feb 4 U.S. Treasuries yields rose on Wednesday after the January reading on a gauge on U.S. private jobs creation supported the view of steady domestic employment growth and revived bets the Federal Reserve might raise interest rates in mid-2015.US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)      U.S. private employers added 213,000 jobs in January, falling short of the median forecasts of analysts, a payrolls processor report showed on Wednesday.TREASURIES-U.S. yields jump after ADP U.S. jobs dataUS STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)      US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     NEW YORK, Feb 4 U.S. Treasuries yields rose on Wednesday after the January reading on a gauge on U.S. private jobs creation supported the view of steady domestic employment growth and revived bets the Federal Reserve might raise interest rates in mid-2015.US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)        U.S. private sector adds 213,000 workers in January: ADPTREASURIES-U.S. yields jump after ADP U.S. jobs dataUS STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)      US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     NEW YORK, Feb 4 U.S. Treasuries yields rose on Wednesday after the January reading on a gauge on U.S. private jobs creation supported the view of steady domestic employment growth and revived bets the Federal Reserve might raise interest rates in mid-2015.US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)       TREASURIES-U.S. yields jump after ADP U.S. jobs dataUS STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)      US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     NEW YORK, Feb 4 U.S. Treasuries yields rose on Wednesday after the January reading on a gauge on U.S. private jobs creation supported the view of steady domestic employment growth and revived bets the Federal Reserve might raise interest rates in mid-2015.US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)      U.S. private employers added 213,000 jobs in January, falling short of the median forecasts of analysts, a payrolls processor report showed on Wednesday.TREASURIES-U.S. yields jump after ADP U.S. jobs dataUS STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)      US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     NEW YORK, Feb 4 U.S. Treasuries yields rose on Wednesday after the January reading on a gauge on U.S. private jobs creation supported the view of steady domestic employment growth and revived bets the Federal Reserve might raise interest rates in mid-2015.US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)       NEW YORK, Feb 4 U.S. stock index futures dipped on Wednesday, after a two-day rally for the S&P; 500 ahead of data on the labor market and the services sector.U.S. private sector adds 213,000 workers in January: ADPTREASURIES-U.S. yields jump after ADP U.S. jobs dataUS STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)      US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     NEW YORK, Feb 4 U.S. Treasuries yields rose on Wednesday after the January reading on a gauge on U.S. private jobs creation supported the view of steady domestic employment growth and revived bets the Federal Reserve might raise interest rates in mid-2015.US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)       TREASURIES-U.S. yields jump after ADP U.S. jobs dataUS STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)      US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     NEW YORK, Feb 4 U.S. Treasuries yields rose on Wednesday after the January reading on a gauge on U.S. private jobs creation supported the view of steady domestic employment growth and revived bets the Federal Reserve might raise interest rates in mid-2015.US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)      U.S. private employers added 213,000 jobs in January, falling short of the median forecasts of analysts, a payrolls processor report showed on Wednesday.TREASURIES-U.S. yields jump after ADP U.S. jobs dataUS STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)      US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     NEW YORK, Feb 4 U.S. Treasuries yields rose on Wednesday after the January reading on a gauge on U.S. private jobs creation supported the view of steady domestic employment growth and revived bets the Federal Reserve might raise interest rates in mid-2015.US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)        
BHI,Many oil firms plan no North Dakota layoffs despite cheap oil WILLISTON, N.D., Feb 4 Halliburton, Statoil ASA, Hess Corp and other North Dakota energy companies have decided, for now, not to lay off staff in the No. 2 U.S. oil producing state, hoping to be prepared for any prolonged rebound in crude prices. 
BSX,Boston Scientific profit falls as litigation costs soarUPDATE 2-Boston Scientific profit beats Street by a cent * Shares touch seven-year high   (Adds detail, analyst comment; updates share)  UPDATE 2-Boston Scientific profit beats Street by a cent * Shares touch seven-year high   (Adds detail, analyst comment; updates share) Feb 4 Medical device maker Boston Scientific Corp posted a 19 percent fall in fourth-quarter profit as litigation charges more than doubled.UPDATE 2-Boston Scientific profit beats Street by a cent * Shares touch seven-year high   (Adds detail, analyst comment; updates share)  
CAH,Whistleblower files U.S. fraud suit against Cardinal HealthWhistleblower files U.S. fraud suit against Cardinal Health Healthcare services provider Cardinal Health Inc said its unit was accused of fraud and violating U.S. healthcare laws by a whistleblower under the False Claims Act.  Whistleblower files U.S. fraud suit against Cardinal Health Healthcare services provider Cardinal Health Inc said its unit was accused of fraud and violating U.S. healthcare laws by a whistleblower under the False Claims Act. Feb 3 Healthcare services provider Cardinal Health Inc said its unit was accused of fraud and violating U.S. healthcare laws by a whistleblower under the False Claims Act.Whistleblower files U.S. fraud suit against Cardinal Health Healthcare services provider Cardinal Health Inc said its unit was accused of fraud and violating U.S. healthcare laws by a whistleblower under the False Claims Act.  
CME,CME Group to close Chicago, New York open-outcry futures trading pits Feb 4 Most open-outcry futures trading pits in Chicago and New York will close by July 2 due to almost all trading having moved to electronic platforms, the CME Group Inc  said on Wednesday. 
CTSH,Cognizant quarterly revenue rises on higher IT spendingUPDATE 3-Cognizant forecasts higher revenue growth as healthcare spending rises * Company's CFO sees significant opportunities in healthcare space  UPDATE 3-Cognizant forecasts higher revenue growth as healthcare spending rises * Company's CFO sees significant opportunities in healthcare space Feb 4 IT services provider Cognizant Technology Solutions Corp reported a 16.4 percent rise in quarterly revenue, helped by higher spending by healthcare and financial services customers.UPDATE 3-Cognizant forecasts higher revenue growth as healthcare spending rises * Company's CFO sees significant opportunities in healthcare space  
CMCSA,UPDATE 2-U.S. FCC chief seeks tighter regulation of Internet providers WASHINGTON, Feb 4 The top U.S. communications regulator on Wednesday proposed to tighten regulations on Internet service providers by treating them more like public utilities, an approach endorsed by President Barack Obama. 
DAL,Delta Air Lines expands partnership with Starbucks Feb 3 Delta Air Lines will serve Starbucks brand coffee on all of its flights, growing its existing partnership with the world's biggest coffee chain, the companies plan to announce on Wednesday. 
EA,CORRECTED-UPDATE 2-'Grand Theft Auto' publisher Take-Two ups full-year profit forecast Feb 3 Take-Two Interactive Software Inc , the publisher of video games such as "Grand Theft Auto", said it expects a slate of unreleased games to drive sales and raised its revenue and profit forecast for the full year. 
ETR,Judge allows hearings on summer closings of New York nuclear plant A judge in New York has ruled Entergy Corp  cannot stop hearings on the state's plan to shut the company's Indian Point nuclear power plant for part of the summer to protect fish in the Hudson River. 
FMC,Tronox to buy FMC's Alkali Chemicals unit for $1.64 blnUPDATE 1-Tronox to buy FMC's soda ash unit for $1.64 bln Feb 3 Diversified chemicals maker Tronox Ltd  said it would acquire FMC Corp's Alkali Chemicals division for $1.64 billion to expand in faster-growing developing economies.  UPDATE 1-Tronox to buy FMC's soda ash unit for $1.64 bln Feb 3 Diversified chemicals maker Tronox Ltd  said it would acquire FMC Corp's Alkali Chemicals division for $1.64 billion to expand in faster-growing developing economies. Feb 3 Diversified chemical maker Tronox Ltd  said it would acquire FMC Corp's Alkali Chemicals business for $1.64 billion.UPDATE 1-Tronox to buy FMC's soda ash unit for $1.64 bln Feb 3 Diversified chemicals maker Tronox Ltd  said it would acquire FMC Corp's Alkali Chemicals division for $1.64 billion to expand in faster-growing developing economies.  
F,Ford adding 1,550 jobs for F-150 production, promotes UAW workersUPDATE 1-Ford adding 1,550 jobs for F-150 production, promotes UAW workersFord adding 1,550 jobs for F-150 production, promotes UAW workersFord CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.  Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade. DETROIT Ford Motor Co said on Wednesday it is adding 1,550 workers at four plants to build the new aluminum body F-150 pickup truck.Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.   Ford adding 1,550 jobs for F-150 production, promotes UAW workersFord CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.  Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade. DETROIT Ford Motor Co said on Wednesday it is adding 1,550 workers at four plants to build the new aluminum body F-150 pickup truck.Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.  DETROIT, Feb 4 Ford Motor Co said on Wednesday it is adding 1,550 workers at four plants to build the new aluminum body F-150 pickup truck.Ford adding 1,550 jobs for F-150 production, promotes UAW workersFord CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.  Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade. DETROIT Ford Motor Co said on Wednesday it is adding 1,550 workers at four plants to build the new aluminum body F-150 pickup truck.Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.    UPDATE 1-Ford adding 1,550 jobs for F-150 production, promotes UAW workersFord adding 1,550 jobs for F-150 production, promotes UAW workersFord CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.  Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade. DETROIT Ford Motor Co said on Wednesday it is adding 1,550 workers at four plants to build the new aluminum body F-150 pickup truck.Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.   Ford adding 1,550 jobs for F-150 production, promotes UAW workersFord CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.  Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade. DETROIT Ford Motor Co said on Wednesday it is adding 1,550 workers at four plants to build the new aluminum body F-150 pickup truck.Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.  DETROIT, Feb 4 Ford Motor Co said on Wednesday it is adding 1,550 workers at four plants to build the new aluminum body F-150 pickup truck.Ford adding 1,550 jobs for F-150 production, promotes UAW workersFord CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.  Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade. DETROIT Ford Motor Co said on Wednesday it is adding 1,550 workers at four plants to build the new aluminum body F-150 pickup truck.Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.   DETROIT, Feb 4 Ford Motor Co said on Wednesday it is adding 1,550 workers at four plants to build the new aluminum body F-150 pickup truck.UPDATE 1-Ford adding 1,550 jobs for F-150 production, promotes UAW workersFord adding 1,550 jobs for F-150 production, promotes UAW workersFord CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.  Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade. DETROIT Ford Motor Co said on Wednesday it is adding 1,550 workers at four plants to build the new aluminum body F-150 pickup truck.Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.   Ford adding 1,550 jobs for F-150 production, promotes UAW workersFord CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.  Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade. DETROIT Ford Motor Co said on Wednesday it is adding 1,550 workers at four plants to build the new aluminum body F-150 pickup truck.Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.  DETROIT, Feb 4 Ford Motor Co said on Wednesday it is adding 1,550 workers at four plants to build the new aluminum body F-150 pickup truck.Ford adding 1,550 jobs for F-150 production, promotes UAW workersFord CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.  Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade. DETROIT Ford Motor Co said on Wednesday it is adding 1,550 workers at four plants to build the new aluminum body F-150 pickup truck.Ford CEO worries cars may get commoditised like mobile handsets BOCHUM, Germany Feb 4 Ford Motor Co Chief Executive Mark Fields said carmakers faced the challenge of avoiding becoming dependent on someone else's business model as companies from new industries increasingly enter the auto trade.    
GM,GM reports much higher-than-expected fourth-quarter profitBRIEF-GM CFO: Russia continues to be a headwind in EuropeUPDATE 2-GM reports higher-than-expected profit despite recall costsBRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video     BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    DETROIT, Feb 4 General Motors Co on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent.BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video      UPDATE 2-GM reports higher-than-expected profit despite recall costsBRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video     BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    DETROIT, Feb 4 General Motors Co on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent.BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video     DETROIT, Feb 4 General Motors Co :  * CFO says biggest headwind in Q4 in Europe was Russia, expects that country toUPDATE 2-GM reports higher-than-expected profit despite recall costsBRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video     BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    DETROIT, Feb 4 General Motors Co on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent.BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video       BRIEF-GM CFO: Russia continues to be a headwind in EuropeUPDATE 2-GM reports higher-than-expected profit despite recall costsBRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video     BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    DETROIT, Feb 4 General Motors Co on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent.BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video      UPDATE 2-GM reports higher-than-expected profit despite recall costsBRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video     BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    DETROIT, Feb 4 General Motors Co on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent.BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video     DETROIT, Feb 4 General Motors Co :  * CFO says biggest headwind in Q4 in Europe was Russia, expects that country toUPDATE 2-GM reports higher-than-expected profit despite recall costsBRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video     BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    DETROIT, Feb 4 General Motors Co on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent.BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video      DETROIT, Feb 4 General Motors Co on Wednesday posted fourth-quarter earnings far above analysts' expectations even as recall costs hit North American profit margins.BRIEF-GM CFO: Russia continues to be a headwind in EuropeUPDATE 2-GM reports higher-than-expected profit despite recall costsBRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video     BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    DETROIT, Feb 4 General Motors Co on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent.BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video      UPDATE 2-GM reports higher-than-expected profit despite recall costsBRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video     BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    DETROIT, Feb 4 General Motors Co on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent.BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video     DETROIT, Feb 4 General Motors Co :  * CFO says biggest headwind in Q4 in Europe was Russia, expects that country toUPDATE 2-GM reports higher-than-expected profit despite recall costsBRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video     BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    DETROIT, Feb 4 General Motors Co on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent.BRIEF-GM CFO: GM Financial profits will be flat in 2015 vs 2014GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video    GM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   DETROIT, Feb 4 General Motors Co :  * CFO says a favorable mix will be a tailwind for the company in 2015, andGM reports higher-than-expected profit despite recall costsExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  DETROIT General Motors Co  on Wednesday posted fourth-quarter earnings far above analysts' expectations as strong sales of high-margin SUVs and trucks in North America helped offset record recall costs there, and its shares rose 3 percent. |Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video  VideoExclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video   Exclusive: Shareholders may get more cash back later in 2015 - GM CFO DETROIT General Motors Co will consider returning more cash to shareholders later this year, on top of a planned 20-percent dividend increase announced Wednesday, the company's chief financial officer told Reuters. |Video       
GILD,Gilead drags healthcare shares down on drug price worriesGilead drags healthcare shares down on drug price worriesUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fall * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)  US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fall * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline) Healthcare shares plunged on Wednesday, lead by biotechnology stocks, after Gilead Sciences Inc said it gave health insurers steeper-than-expected discounts on its hepatitis C drugs, fueling worries that the broader sector would face increasing price pressure.US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fall * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)   Gilead drags healthcare shares down on drug price worriesUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fall * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)  US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fall * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline) Healthcare shares plunged on Wednesday, lead by biotechnology stocks, after Gilead Sciences Inc said it gave health insurers steeper-than-expected discounts on its hepatitis C drugs, fueling worries that the broader sector would face increasing price pressure.US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fall * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)  Feb 4 Healthcare shares plunged on Wednesday, lead by biotechnology stocks, after Gilead Sciences Inc  said it gave health insurers steeper-than-expected discounts on its hepatitis C drugs, fueling worries that the broader sector would face increasing price pressure.Gilead drags healthcare shares down on drug price worriesUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fall * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)  US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fall * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline) Healthcare shares plunged on Wednesday, lead by biotechnology stocks, after Gilead Sciences Inc said it gave health insurers steeper-than-expected discounts on its hepatitis C drugs, fueling worries that the broader sector would face increasing price pressure.US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fall * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)   
HAL,Many oil firms plan no North Dakota layoffs despite cheap oil WILLISTON, N.D., Feb 4 Halliburton, Statoil ASA, Hess Corp and other North Dakota energy companies have decided, for now, not to lay off staff in the No. 2 U.S. oil producing state, hoping to be prepared for any prolonged rebound in crude prices. 
HES,Many oil firms plan no North Dakota layoffs despite cheap oil WILLISTON, N.D., Feb 4 Halliburton, Statoil ASA, Hess Corp and other North Dakota energy companies have decided, for now, not to lay off staff in the No. 2 U.S. oil producing state, hoping to be prepared for any prolonged rebound in crude prices. 
HUM,Health insurer Humana reports pretax profitUPDATE 2-Humana profit misses but shares rise on 2015 outlook Feb 4 U.S. health insurer Humana Inc  reported a lower-than- expected fourth-quarter profit as it spent more on new hepatitis C treatments and flu season expenses increased, but it said those and other costs are behind it and predicted a better 2015.  UPDATE 2-Humana profit misses but shares rise on 2015 outlook Feb 4 U.S. health insurer Humana Inc  reported a lower-than- expected fourth-quarter profit as it spent more on new hepatitis C treatments and flu season expenses increased, but it said those and other costs are behind it and predicted a better 2015. Feb  4U.S. health insurer Humana Inc  posted a pretax profit for the fourth quarter, compared with a loss a year earlier, reflecting a rise in individual Medicare Advantage memberships.UPDATE 2-Humana profit misses but shares rise on 2015 outlook Feb 4 U.S. health insurer Humana Inc  reported a lower-than- expected fourth-quarter profit as it spent more on new hepatitis C treatments and flu season expenses increased, but it said those and other costs are behind it and predicted a better 2015.  
LUK,Jefferies CEO Richard Handler turns down bonus Feb 4 Richard Handler, the chief executive of Leucadia National Corp, parent of investment bank Jefferies Group LLC, turned down his bonus for the previous year, which was dogged by lackluster performance. 
LMT,Lockheed CTO Ray Johnson retires WASHINGTON, Feb 4 Lockheed Martin Corp  Chief Technology Officer Ray Johnson retired on Feb. 1, a company spokeswoman told Reuters on Wednesday. 
MPC,UPDATE 1-Marathon defers decision on Garyville, La. refinery oil upgrader Feb 4 Marathon Petroleum Corp said it was deferring a final investment decision on its residual oil upgrader expansion (ROUX) project at its 522,000-barrel-per-day Garyville, Louisiana, refinery. 
MCD,McDonald's Japan set for more earnings pain after food safety scandals TOKYO, Feb 5 The Japanese unit of McDonald's Corp is likely to post a second straight year of losses in 2015 as it grapples with the fallout from food safety scandals and a french fry shortage, exacerbating headaches for a global brand struggling to appeal to consumers. 
MRK,Merck issues cautious 2015 forecast, citing dollarUS STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.      US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.       US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.      US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.      * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.      US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.        US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.      US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.       US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.      US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.      * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.      US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.       Feb 4 Merck & Co on Wednesday reported slightly disappointing fourth quarter sales and predicted 2015 earnings below analyst forecasts, citing the negative impact of the stronger dollar, as most of its U.S. rivals have done in making their own cautious forecasts.US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.      US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.       US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.      US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.      * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.      US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-Wall St dips after 2-day run as energy rally stallsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.     US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    * Indexes: Dow up 0.16 pct, S&P; off 0.22 pct, Nasdaq 0.31 pct   (Adds ISM services data)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.    UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)UPDATE 3-Merck says hepatitis C treatment to lose "breakthrough" statusUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.   US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Feb 4 Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oilMerck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.  Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months. * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)Merck says hepatitis C treatment to lose "breakthrough" status Merck & Co on Wednesday said U.S. regulators intend to rescind the "breakthrough therapy" designation for its  combination treatment for hepatitis C because other new drugs are available, a decision that could delay approval of the Merck product by several months.        
MSI,Motorola Solutions profit beats estimates on lower expensesUPDATE 1-Motorola Solutions revenue, forecast beat on strong N. America sales Feb 4 Motorola Solutions Inc, a maker of walkie-talkies and radio systems, reported better-than-expected quarterly revenue and forecast a smaller-than-expected fall in sales in the current quarter, helped by increasing demand in North America.  UPDATE 1-Motorola Solutions revenue, forecast beat on strong N. America sales Feb 4 Motorola Solutions Inc, a maker of walkie-talkies and radio systems, reported better-than-expected quarterly revenue and forecast a smaller-than-expected fall in sales in the current quarter, helped by increasing demand in North America. Feb 4 Motorola Solutions Inc, a maker of walkie-talkies and radio systems, reported a better-than-expected quarterly profit, helped by lower operating expenses.UPDATE 1-Motorola Solutions revenue, forecast beat on strong N. America sales Feb 4 Motorola Solutions Inc, a maker of walkie-talkies and radio systems, reported better-than-expected quarterly revenue and forecast a smaller-than-expected fall in sales in the current quarter, helped by increasing demand in North America.  
NFLX,Netflix to enter Japan in fall of 2015 -source Feb 4 Netflix Inc will launch its movie and TV streaming service in Japan in the fall of 2015, a source with knowledge of the matter said on Wednesday. 
NWSA,Saudi's Kingdom Holding says sells 5.6 pct stake in News CorpSaudi's Kingdom Holding sells 5.6 percent stake in News Corp DUBAI Saudi Arabia's Kingdom Holding , the investment firm owned by billionaire Prince Alwaleed bin Talal, sold most of its stake in media giant News Corp  as part of a portfolio review, it said on Wednesday.  Saudi's Kingdom Holding sells 5.6 percent stake in News Corp DUBAI Saudi Arabia's Kingdom Holding , the investment firm owned by billionaire Prince Alwaleed bin Talal, sold most of its stake in media giant News Corp  as part of a portfolio review, it said on Wednesday. DUBAI, Feb 4 Saudi Arabia's Kingdom Holding , the investment firm owned by billionaire Prince Alwaleed bin Talal, reduced the size of its stake in media giant News Corp by 5.6 percent, it said on Wednesday.Saudi's Kingdom Holding sells 5.6 percent stake in News Corp DUBAI Saudi Arabia's Kingdom Holding , the investment firm owned by billionaire Prince Alwaleed bin Talal, sold most of its stake in media giant News Corp  as part of a portfolio review, it said on Wednesday.  
NWS,Saudi's Kingdom Holding says sells 5.6 pct stake in News CorpSaudi's Kingdom Holding sells 5.6 percent stake in News Corp DUBAI Saudi Arabia's Kingdom Holding , the investment firm owned by billionaire Prince Alwaleed bin Talal, sold most of its stake in media giant News Corp  as part of a portfolio review, it said on Wednesday.  Saudi's Kingdom Holding sells 5.6 percent stake in News Corp DUBAI Saudi Arabia's Kingdom Holding , the investment firm owned by billionaire Prince Alwaleed bin Talal, sold most of its stake in media giant News Corp  as part of a portfolio review, it said on Wednesday. DUBAI, Feb 4 Saudi Arabia's Kingdom Holding , the investment firm owned by billionaire Prince Alwaleed bin Talal, reduced the size of its stake in media giant News Corp by 5.6 percent, it said on Wednesday.Saudi's Kingdom Holding sells 5.6 percent stake in News Corp DUBAI Saudi Arabia's Kingdom Holding , the investment firm owned by billionaire Prince Alwaleed bin Talal, sold most of its stake in media giant News Corp  as part of a portfolio review, it said on Wednesday.  
RL,Ralph Lauren's quarterly profit falls 9.3 pctUPDATE 1-Ralph Lauren cuts full-year revenue growth forecast again Feb 4 Luxury fashion house Ralph Lauren Corp  cut its full-year revenue growth forecast for the second time in less than four months, blaming a strong dollar and weak consumer spending.  UPDATE 1-Ralph Lauren cuts full-year revenue growth forecast again Feb 4 Luxury fashion house Ralph Lauren Corp  cut its full-year revenue growth forecast for the second time in less than four months, blaming a strong dollar and weak consumer spending. Feb 4 Ralph Lauren Corp reported a 9.3 percent drop in quarterly profit, hurt by a stronger dollar and lower-than-expected sales, sending its shares down 9.7 percent in premarket trading.UPDATE 1-Ralph Lauren cuts full-year revenue growth forecast again Feb 4 Luxury fashion house Ralph Lauren Corp  cut its full-year revenue growth forecast for the second time in less than four months, blaming a strong dollar and weak consumer spending.  
PG,UPDATE 3-J M Smucker to buy Meow Mix owner in pet food push * Total deal value of about $5.8 bln, including $2.6 bln debt 
PRU,Prudential Financial's quarterly net loss widens Feb 4 Life insurer Prudential Financial Inc's  quarterly net loss widened, due partly to losses related to the dollar's strength against the Japanese yen. 
SLB,Many oil firms plan no North Dakota layoffs despite cheap oil WILLISTON, N.D., Feb 4 Halliburton, Statoil ASA, Hess Corp and other North Dakota energy companies have decided, for now, not to lay off staff in the No. 2 U.S. oil producing state, hoping to be prepared for any prolonged rebound in crude prices. 
SJM,UPDATE 3-J M Smucker to buy Meow Mix owner in pet food pushJ M Smucker to buy Meow Mix owner in pet food pushJ M Smucker to buy Meow Mix owner in pet food push J M Smucker Co has agreed to buy Big Heart Pet Brands for $3.2 billion, snapping up the popular Meow Mix and Milk-Bone brands in its first venture into the fast-growing U.S. pet food market.  J M Smucker to buy Meow Mix owner in pet food push J M Smucker Co has agreed to buy Big Heart Pet Brands for $3.2 billion, snapping up the popular Meow Mix and Milk-Bone brands in its first venture into the fast-growing U.S. pet food market. J M Smucker Co  has agreed to buy Big Heart Pet Brands for $3.2 billion, snapping up the popular Meow Mix and Milk-Bone brands in its first venture into the fast-growing U.S. pet food market.J M Smucker to buy Meow Mix owner in pet food push J M Smucker Co has agreed to buy Big Heart Pet Brands for $3.2 billion, snapping up the popular Meow Mix and Milk-Bone brands in its first venture into the fast-growing U.S. pet food market.   J M Smucker to buy Meow Mix owner in pet food pushJ M Smucker to buy Meow Mix owner in pet food push J M Smucker Co has agreed to buy Big Heart Pet Brands for $3.2 billion, snapping up the popular Meow Mix and Milk-Bone brands in its first venture into the fast-growing U.S. pet food market.  J M Smucker to buy Meow Mix owner in pet food push J M Smucker Co has agreed to buy Big Heart Pet Brands for $3.2 billion, snapping up the popular Meow Mix and Milk-Bone brands in its first venture into the fast-growing U.S. pet food market. J M Smucker Co  has agreed to buy Big Heart Pet Brands for $3.2 billion, snapping up the popular Meow Mix and Milk-Bone brands in its first venture into the fast-growing U.S. pet food market.J M Smucker to buy Meow Mix owner in pet food push J M Smucker Co has agreed to buy Big Heart Pet Brands for $3.2 billion, snapping up the popular Meow Mix and Milk-Bone brands in its first venture into the fast-growing U.S. pet food market.  * Total deal value of about $5.8 bln, including $2.6 bln debtJ M Smucker to buy Meow Mix owner in pet food pushJ M Smucker to buy Meow Mix owner in pet food push J M Smucker Co has agreed to buy Big Heart Pet Brands for $3.2 billion, snapping up the popular Meow Mix and Milk-Bone brands in its first venture into the fast-growing U.S. pet food market.  J M Smucker to buy Meow Mix owner in pet food push J M Smucker Co has agreed to buy Big Heart Pet Brands for $3.2 billion, snapping up the popular Meow Mix and Milk-Bone brands in its first venture into the fast-growing U.S. pet food market. J M Smucker Co  has agreed to buy Big Heart Pet Brands for $3.2 billion, snapping up the popular Meow Mix and Milk-Bone brands in its first venture into the fast-growing U.S. pet food market.J M Smucker to buy Meow Mix owner in pet food push J M Smucker Co has agreed to buy Big Heart Pet Brands for $3.2 billion, snapping up the popular Meow Mix and Milk-Bone brands in its first venture into the fast-growing U.S. pet food market.   
SPLS,Staples to buy Office Depot for $6.3 blnBreakingviews: Staples-Office Depot can pass antitrust checkoutUPDATE 4-Staples agrees to buy Office Depot, FTC approval seen likelyDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.    Deals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   * Deal aimed at competing better with online and big box rivalsDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.     UPDATE 4-Staples agrees to buy Office Depot, FTC approval seen likelyDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.    Deals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   * Deal aimed at competing better with online and big box rivalsDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.    NEW YORK (Reuters Breakingviews) - Staples' $6.3 billion takeover of Office Depot could slide through the antitrust checkout line. Crunching together the two largest U.S. office supply chains is a financial winner: the value of the synergies alone almost pays for the entire deal. And though trustbusters may squawk, even they acknowledge that, with internet and big box stores thriving, the competitive landscape has changed.UPDATE 4-Staples agrees to buy Office Depot, FTC approval seen likelyDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.    Deals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   * Deal aimed at competing better with online and big box rivalsDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.      Breakingviews: Staples-Office Depot can pass antitrust checkoutUPDATE 4-Staples agrees to buy Office Depot, FTC approval seen likelyDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.    Deals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   * Deal aimed at competing better with online and big box rivalsDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.     UPDATE 4-Staples agrees to buy Office Depot, FTC approval seen likelyDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.    Deals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   * Deal aimed at competing better with online and big box rivalsDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.    NEW YORK (Reuters Breakingviews) - Staples' $6.3 billion takeover of Office Depot could slide through the antitrust checkout line. Crunching together the two largest U.S. office supply chains is a financial winner: the value of the synergies alone almost pays for the entire deal. And though trustbusters may squawk, even they acknowledge that, with internet and big box stores thriving, the competitive landscape has changed.UPDATE 4-Staples agrees to buy Office Depot, FTC approval seen likelyDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.    Deals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   * Deal aimed at competing better with online and big box rivalsDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.     Feb 4 Staples Inc, the No. 1 U.S. office supplier, said it would buy its nearest rival Office Depot Inc in a $6.3 billion cash-and-stock deal.Breakingviews: Staples-Office Depot can pass antitrust checkoutUPDATE 4-Staples agrees to buy Office Depot, FTC approval seen likelyDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.    Deals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   * Deal aimed at competing better with online and big box rivalsDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.     UPDATE 4-Staples agrees to buy Office Depot, FTC approval seen likelyDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.    Deals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   * Deal aimed at competing better with online and big box rivalsDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.    NEW YORK (Reuters Breakingviews) - Staples' $6.3 billion takeover of Office Depot could slide through the antitrust checkout line. Crunching together the two largest U.S. office supply chains is a financial winner: the value of the synergies alone almost pays for the entire deal. And though trustbusters may squawk, even they acknowledge that, with internet and big box stores thriving, the competitive landscape has changed.UPDATE 4-Staples agrees to buy Office Depot, FTC approval seen likelyDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.    Deals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   * Deal aimed at competing better with online and big box rivalsDeals of the day- Mergers and acquisitionsStaples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.   Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  Feb 4 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Wednesday:Staples, Office Depot expect second time a charm in mergerUPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.  UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday. Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.UPDATE 6-Staples, Office Depot expect second time a charm in merger Feb 4 Staples Inc and Office Depot  should find the second time is a charm as the top two U.S. office supply chains once again test the views of antitrust regulators in the rapidly changing retail landscape, experts said on Wednesday.      
SBUX,Delta Air Lines expands partnership with StarbucksDelta Air Lines expands partnership with StarbucksStarbucks' U.S. shops turn to coconuts as non-dairy demand soars Feb 4 Starbucks Corp said on Wednesday that its 12,123 U.S. shops would begin offering coconut milk on Feb. 17, as it seeks to keep pace with soaring demand for non-dairy and non-soy milk alternatives.  Starbucks' U.S. shops turn to coconuts as non-dairy demand soars Feb 4 Starbucks Corp said on Wednesday that its 12,123 U.S. shops would begin offering coconut milk on Feb. 17, as it seeks to keep pace with soaring demand for non-dairy and non-soy milk alternatives. Delta Air Lines will serve Starbucks brand coffee on all of its flights, growing its existing partnership with the world's biggest coffee chain, the companies plan to announce on Wednesday.Starbucks' U.S. shops turn to coconuts as non-dairy demand soars Feb 4 Starbucks Corp said on Wednesday that its 12,123 U.S. shops would begin offering coconut milk on Feb. 17, as it seeks to keep pace with soaring demand for non-dairy and non-soy milk alternatives.   Delta Air Lines expands partnership with StarbucksStarbucks' U.S. shops turn to coconuts as non-dairy demand soars Feb 4 Starbucks Corp said on Wednesday that its 12,123 U.S. shops would begin offering coconut milk on Feb. 17, as it seeks to keep pace with soaring demand for non-dairy and non-soy milk alternatives.  Starbucks' U.S. shops turn to coconuts as non-dairy demand soars Feb 4 Starbucks Corp said on Wednesday that its 12,123 U.S. shops would begin offering coconut milk on Feb. 17, as it seeks to keep pace with soaring demand for non-dairy and non-soy milk alternatives. Delta Air Lines will serve Starbucks brand coffee on all of its flights, growing its existing partnership with the world's biggest coffee chain, the companies plan to announce on Wednesday.Starbucks' U.S. shops turn to coconuts as non-dairy demand soars Feb 4 Starbucks Corp said on Wednesday that its 12,123 U.S. shops would begin offering coconut milk on Feb. 17, as it seeks to keep pace with soaring demand for non-dairy and non-soy milk alternatives.  Feb 3 Delta Air Lines will serve Starbucks brand coffee on all of its flights, growing its existing partnership with the world's biggest coffee chain, the companies plan to announce on Wednesday.Delta Air Lines expands partnership with StarbucksStarbucks' U.S. shops turn to coconuts as non-dairy demand soars Feb 4 Starbucks Corp said on Wednesday that its 12,123 U.S. shops would begin offering coconut milk on Feb. 17, as it seeks to keep pace with soaring demand for non-dairy and non-soy milk alternatives.  Starbucks' U.S. shops turn to coconuts as non-dairy demand soars Feb 4 Starbucks Corp said on Wednesday that its 12,123 U.S. shops would begin offering coconut milk on Feb. 17, as it seeks to keep pace with soaring demand for non-dairy and non-soy milk alternatives. Delta Air Lines will serve Starbucks brand coffee on all of its flights, growing its existing partnership with the world's biggest coffee chain, the companies plan to announce on Wednesday.Starbucks' U.S. shops turn to coconuts as non-dairy demand soars Feb 4 Starbucks Corp said on Wednesday that its 12,123 U.S. shops would begin offering coconut milk on Feb. 17, as it seeks to keep pace with soaring demand for non-dairy and non-soy milk alternatives.   
TSO,Tough talk from Shell, union as U.S. refinery pay talks resumeTough talk from Shell, union as U.S. refinery pay talks resumeTwo states looking at Tesoro's and Marathon's strike plans NEW YORK Tesoro Corp  and Marathon Petroleum Corp's  contingency plans to employ replacement workers at two of their refineries after union employees hit the picket lines are under scrutiny by inspectors in both Kentucky and California, officials of the two states said Wednesday.  Two states looking at Tesoro's and Marathon's strike plans NEW YORK Tesoro Corp  and Marathon Petroleum Corp's  contingency plans to employ replacement workers at two of their refineries after union employees hit the picket lines are under scrutiny by inspectors in both Kentucky and California, officials of the two states said Wednesday. HOUSTON Negotiations made no progress on Tuesday as Royal Dutch Shell Plc and union leaders haggled over a new wage contract for U.S. refinery workers who have been on strike for three days, the union said.Two states looking at Tesoro's and Marathon's strike plans NEW YORK Tesoro Corp  and Marathon Petroleum Corp's  contingency plans to employ replacement workers at two of their refineries after union employees hit the picket lines are under scrutiny by inspectors in both Kentucky and California, officials of the two states said Wednesday.   Tough talk from Shell, union as U.S. refinery pay talks resumeTwo states looking at Tesoro's and Marathon's strike plans NEW YORK Tesoro Corp  and Marathon Petroleum Corp's  contingency plans to employ replacement workers at two of their refineries after union employees hit the picket lines are under scrutiny by inspectors in both Kentucky and California, officials of the two states said Wednesday.  Two states looking at Tesoro's and Marathon's strike plans NEW YORK Tesoro Corp  and Marathon Petroleum Corp's  contingency plans to employ replacement workers at two of their refineries after union employees hit the picket lines are under scrutiny by inspectors in both Kentucky and California, officials of the two states said Wednesday. HOUSTON Negotiations made no progress on Tuesday as Royal Dutch Shell Plc and union leaders haggled over a new wage contract for U.S. refinery workers who have been on strike for three days, the union said.Two states looking at Tesoro's and Marathon's strike plans NEW YORK Tesoro Corp  and Marathon Petroleum Corp's  contingency plans to employ replacement workers at two of their refineries after union employees hit the picket lines are under scrutiny by inspectors in both Kentucky and California, officials of the two states said Wednesday.  HOUSTON Negotiations made no progress on Tuesday as Royal Dutch Shell Plc and union leaders haggled over a new wage contract for U.S. refinery workers who have been on strike for three days, the union said.Tough talk from Shell, union as U.S. refinery pay talks resumeTwo states looking at Tesoro's and Marathon's strike plans NEW YORK Tesoro Corp  and Marathon Petroleum Corp's  contingency plans to employ replacement workers at two of their refineries after union employees hit the picket lines are under scrutiny by inspectors in both Kentucky and California, officials of the two states said Wednesday.  Two states looking at Tesoro's and Marathon's strike plans NEW YORK Tesoro Corp  and Marathon Petroleum Corp's  contingency plans to employ replacement workers at two of their refineries after union employees hit the picket lines are under scrutiny by inspectors in both Kentucky and California, officials of the two states said Wednesday. HOUSTON Negotiations made no progress on Tuesday as Royal Dutch Shell Plc and union leaders haggled over a new wage contract for U.S. refinery workers who have been on strike for three days, the union said.Two states looking at Tesoro's and Marathon's strike plans NEW YORK Tesoro Corp  and Marathon Petroleum Corp's  contingency plans to employ replacement workers at two of their refineries after union employees hit the picket lines are under scrutiny by inspectors in both Kentucky and California, officials of the two states said Wednesday.   
DIS,'Frozen' still hot as Disney profit beats forecastsUS STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    Walt Disney Co's  quarterly profit topped Wall Street's  estimates as its blockbuster animated film "Frozen" heated up home entertainment and toy sales, and visitors flocked to the company's U.S. theme parks. |US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    VideoUS STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     US STOCKS-Wall St to open lower after 2-day run, ADP dataUS STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)    US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   * Futures off: Dow 18 pts, S&P; 6.25 pts, Nasdaq 14.5 pts   (Adds ADP data, quote)US STOCKS-Wall St down after 2-day run after ADP as energy dragsUS STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)   US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  * Indexes off: Dow 0.2 pct, S&P; 0.47 pct, Nasdaq 0.59 pct   (Updates to market open)US STOCKS-S&P;, Nasdaq down after 2-day run up; biotechs, energy fallUS STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)  US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon) * Indexes: Dow up 0.1 pct, S&P; off 0.4 pct, Nasdaq down 0.2 pct   (Updates to midday, changes byline)US STOCKS-S&P;, Nasdaq slip after 2-day run up; energy drops with oil * Indexes: Dow up 0.1 pct, S&P; off 0.3 pct, Nasdaq down 0.1 pct   (Updates to afternoon)     
FOXA,Saudi's Kingdom Holding sells 5.6 percent stake in News CorpUPDATE 1-Cable business, films help Fox beat estimates Feb 4 Twenty-First Century Fox Inc's  quarterly profit beat analysts' estimates, helped by higher affiliate and advertising revenue in its cable business and the box-office success of "The Maze Runner" and "Gone Girl".  UPDATE 1-Cable business, films help Fox beat estimates Feb 4 Twenty-First Century Fox Inc's  quarterly profit beat analysts' estimates, helped by higher affiliate and advertising revenue in its cable business and the box-office success of "The Maze Runner" and "Gone Girl". DUBAI Saudi Arabia's Kingdom Holding , the investment firm owned by billionaire Prince Alwaleed bin Talal, sold most of its stake in media giant News Corp  as part of a portfolio review, it said on Wednesday.UPDATE 1-Cable business, films help Fox beat estimates Feb 4 Twenty-First Century Fox Inc's  quarterly profit beat analysts' estimates, helped by higher affiliate and advertising revenue in its cable business and the box-office success of "The Maze Runner" and "Gone Girl".  
FOX,Saudi's Kingdom Holding sells 5.6 percent stake in News CorpUPDATE 1-Cable business, films help Fox beat estimates Feb 4 Twenty-First Century Fox Inc's  quarterly profit beat analysts' estimates, helped by higher affiliate and advertising revenue in its cable business and the box-office success of "The Maze Runner" and "Gone Girl".  UPDATE 1-Cable business, films help Fox beat estimates Feb 4 Twenty-First Century Fox Inc's  quarterly profit beat analysts' estimates, helped by higher affiliate and advertising revenue in its cable business and the box-office success of "The Maze Runner" and "Gone Girl". DUBAI Saudi Arabia's Kingdom Holding , the investment firm owned by billionaire Prince Alwaleed bin Talal, sold most of its stake in media giant News Corp  as part of a portfolio review, it said on Wednesday.UPDATE 1-Cable business, films help Fox beat estimates Feb 4 Twenty-First Century Fox Inc's  quarterly profit beat analysts' estimates, helped by higher affiliate and advertising revenue in its cable business and the box-office success of "The Maze Runner" and "Gone Girl".  
USB,UPDATE 1-U.S. Bancorp to pay $18 mln to customers of failed Peregrine NEW YORK/WASHINGTON, Feb 4 U.S. Bancorp agreed to pay $18 million to former customers of Peregrine Financial Group Inc to resolve claims that the large U.S. bank aided a massive fraud by the failed futures brokerage's now-imprisoned founder, Russell Wasendorf Sr. 
UTX,BRIEF-United FY 2014 revenue up 70 pct yoyUnited Tech sees possible cost benefit from low commodity pricesUPDATE 2-United Tech may see $75 mln cost benefit from lower commod prices-CFO Feb 4 United Technologies Corp could see savings of as much as $75 million this year from lower prices for oil and other commodities, although it may have to cede some of those benefits  to customers, its finance chief said on Wednesday.  UPDATE 2-United Tech may see $75 mln cost benefit from lower commod prices-CFO Feb 4 United Technologies Corp could see savings of as much as $75 million this year from lower prices for oil and other commodities, although it may have to cede some of those benefits  to customers, its finance chief said on Wednesday. Feb 4 United Technologies Corp could see savings of as much as $75 million this year from lower prices for oil and other commodities, although it may have to cede some of those benefits  to customers, its finance chief said on Wednesday.UPDATE 2-United Tech may see $75 mln cost benefit from lower commod prices-CFO Feb 4 United Technologies Corp could see savings of as much as $75 million this year from lower prices for oil and other commodities, although it may have to cede some of those benefits  to customers, its finance chief said on Wednesday.   United Tech sees possible cost benefit from low commodity pricesUPDATE 2-United Tech may see $75 mln cost benefit from lower commod prices-CFO Feb 4 United Technologies Corp could see savings of as much as $75 million this year from lower prices for oil and other commodities, although it may have to cede some of those benefits  to customers, its finance chief said on Wednesday.  UPDATE 2-United Tech may see $75 mln cost benefit from lower commod prices-CFO Feb 4 United Technologies Corp could see savings of as much as $75 million this year from lower prices for oil and other commodities, although it may have to cede some of those benefits  to customers, its finance chief said on Wednesday. Feb 4 United Technologies Corp could see savings of as much as $75 million this year from lower prices for oil and other commodities, although it may have to cede some of those benefits  to customers, its finance chief said on Wednesday.UPDATE 2-United Tech may see $75 mln cost benefit from lower commod prices-CFO Feb 4 United Technologies Corp could see savings of as much as $75 million this year from lower prices for oil and other commodities, although it may have to cede some of those benefits  to customers, its finance chief said on Wednesday.  * Said on Tuesday that its estimated FY 2014 revenue is over 19 million zlotys ($5.2 million), up 70 pct year on yearUnited Tech sees possible cost benefit from low commodity pricesUPDATE 2-United Tech may see $75 mln cost benefit from lower commod prices-CFO Feb 4 United Technologies Corp could see savings of as much as $75 million this year from lower prices for oil and other commodities, although it may have to cede some of those benefits  to customers, its finance chief said on Wednesday.  UPDATE 2-United Tech may see $75 mln cost benefit from lower commod prices-CFO Feb 4 United Technologies Corp could see savings of as much as $75 million this year from lower prices for oil and other commodities, although it may have to cede some of those benefits  to customers, its finance chief said on Wednesday. Feb 4 United Technologies Corp could see savings of as much as $75 million this year from lower prices for oil and other commodities, although it may have to cede some of those benefits  to customers, its finance chief said on Wednesday.UPDATE 2-United Tech may see $75 mln cost benefit from lower commod prices-CFO Feb 4 United Technologies Corp could see savings of as much as $75 million this year from lower prices for oil and other commodities, although it may have to cede some of those benefits  to customers, its finance chief said on Wednesday.   
WHR,Whirlpool profit drops due to acquisition costsUPDATE 2-Whirlpool expects robust U.S. growth, but dollar to dragWhirlpool expects robust U.S. growth, but dollar to drag CHICAGO Whirlpool Corp  on Wednesday said 2015 would be another solid year for U.S. sales of its washers, stoves and refrigerators because of the housing market's recovery and low oil prices, and its shares rose 6 percent.  Whirlpool expects robust U.S. growth, but dollar to drag CHICAGO Whirlpool Corp  on Wednesday said 2015 would be another solid year for U.S. sales of its washers, stoves and refrigerators because of the housing market's recovery and low oil prices, and its shares rose 6 percent. CHICAGO, Feb 4 Whirlpool Corp on Wednesday said 2015 would be another solid year for U.S. sales of its washers, stoves and refrigerators because of the housing market's recovery and low oil prices, and its shares rose 6 percent.Whirlpool expects robust U.S. growth, but dollar to drag CHICAGO Whirlpool Corp  on Wednesday said 2015 would be another solid year for U.S. sales of its washers, stoves and refrigerators because of the housing market's recovery and low oil prices, and its shares rose 6 percent.   UPDATE 2-Whirlpool expects robust U.S. growth, but dollar to dragWhirlpool expects robust U.S. growth, but dollar to drag CHICAGO Whirlpool Corp  on Wednesday said 2015 would be another solid year for U.S. sales of its washers, stoves and refrigerators because of the housing market's recovery and low oil prices, and its shares rose 6 percent.  Whirlpool expects robust U.S. growth, but dollar to drag CHICAGO Whirlpool Corp  on Wednesday said 2015 would be another solid year for U.S. sales of its washers, stoves and refrigerators because of the housing market's recovery and low oil prices, and its shares rose 6 percent. CHICAGO, Feb 4 Whirlpool Corp on Wednesday said 2015 would be another solid year for U.S. sales of its washers, stoves and refrigerators because of the housing market's recovery and low oil prices, and its shares rose 6 percent.Whirlpool expects robust U.S. growth, but dollar to drag CHICAGO Whirlpool Corp  on Wednesday said 2015 would be another solid year for U.S. sales of its washers, stoves and refrigerators because of the housing market's recovery and low oil prices, and its shares rose 6 percent.  CHICAGO, Feb 4 Whirlpool Corp on Wednesday posted a lower quarterly profit, hurt by costs from two recent acquisitions.UPDATE 2-Whirlpool expects robust U.S. growth, but dollar to dragWhirlpool expects robust U.S. growth, but dollar to drag CHICAGO Whirlpool Corp  on Wednesday said 2015 would be another solid year for U.S. sales of its washers, stoves and refrigerators because of the housing market's recovery and low oil prices, and its shares rose 6 percent.  Whirlpool expects robust U.S. growth, but dollar to drag CHICAGO Whirlpool Corp  on Wednesday said 2015 would be another solid year for U.S. sales of its washers, stoves and refrigerators because of the housing market's recovery and low oil prices, and its shares rose 6 percent. CHICAGO, Feb 4 Whirlpool Corp on Wednesday said 2015 would be another solid year for U.S. sales of its washers, stoves and refrigerators because of the housing market's recovery and low oil prices, and its shares rose 6 percent.Whirlpool expects robust U.S. growth, but dollar to drag CHICAGO Whirlpool Corp  on Wednesday said 2015 would be another solid year for U.S. sales of its washers, stoves and refrigerators because of the housing market's recovery and low oil prices, and its shares rose 6 percent.   
YHOO,Yahoo to spin off Small Business unit with Alibaba stake Feb 3 Yahoo has decided to spin off its Small Business unit as part of the spinoff of its stake in Alibaba Group Holding Ltd. 
ZTS,Hedge fund Pershing Square wins board seat at ZoetisExclusive: Ackman poised to win Zoetis board seats - sources Hedge fund Pershing Square Capital Management is pressing for seats on animal health company Zoetis Inc's board of directors, with an eye to pushing through cost cuts and a possible merger, according to sources familiar with the negotiations.  Exclusive: Ackman poised to win Zoetis board seats - sources Hedge fund Pershing Square Capital Management is pressing for seats on animal health company Zoetis Inc's board of directors, with an eye to pushing through cost cuts and a possible merger, according to sources familiar with the negotiations. BOSTON, Feb 4 Hedge fund Pershing Square Capital Management won one seat on the board of directors of animal health company Zoetis Inc and agreed with management to select a second "mutually agreeable" director, Zoetis said on Wednesday.Exclusive: Ackman poised to win Zoetis board seats - sources Hedge fund Pershing Square Capital Management is pressing for seats on animal health company Zoetis Inc's board of directors, with an eye to pushing through cost cuts and a possible merger, according to sources familiar with the negotiations.  
